GP2 peptide

DB16180Investigational

GP2 peptide is under investigation in clinical trial NCT00524277 (Vaccine Therapy in Treating Patients With Breast Cancer).

Also known as
Gp-2 her2-derived, hla-a2+ restricted peptide
Code names
GP-2

Resolves to

Compound
UNIIFQA52PV28GCAS160790-21-6

What you can answer from here — as of April 23, 2025

2Clinical trialsPhase, status and sponsor resolved per trial
Sign in

Which companies are running trials of GP2 peptide, in which indications and phases, and which of those programs are still active?

Answer this in Biopharma OSSign in to your account

Create a free account or log in to explore the full data card.

Create Account
Log InPaid Account Log In